Geode Capital Management LLC lowered its position in Diplomat Pharmacy, Inc. (NYSE:DPLO) by 28.1% during the first quarter, Holdings Channel reports. The fund owned 324,194 shares of the company’s stock after selling 126,513 shares during the period. Geode Capital Management LLC’s holdings in Diplomat Pharmacy were worth $5,170,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Frontier Capital Management Co. LLC acquired a new position in shares of Diplomat Pharmacy during the first quarter worth about $87,015,000. Vanguard Group Inc. increased its position in shares of Diplomat Pharmacy by 14.2% in the first quarter. Vanguard Group Inc. now owns 3,866,811 shares of the company’s stock worth $61,676,000 after buying an additional 481,710 shares during the last quarter. Hermes Investment Management Ltd. increased its position in shares of Diplomat Pharmacy by 17.2% in the first quarter. Hermes Investment Management Ltd. now owns 1,772,777 shares of the company’s stock worth $28,276,000 after buying an additional 259,696 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Diplomat Pharmacy by 52,972.3% in the first quarter. Victory Capital Management Inc. now owns 961,140 shares of the company’s stock worth $15,330,000 after buying an additional 959,329 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Diplomat Pharmacy by 4.2% in the first quarter. Bank of New York Mellon Corp now owns 572,791 shares of the company’s stock worth $9,137,000 after buying an additional 23,074 shares during the last quarter. 72.02% of the stock is currently owned by institutional investors and hedge funds.

Shares of Diplomat Pharmacy, Inc. (DPLO) traded up 1.63% during midday trading on Friday, hitting $16.20. 733,956 shares of the stock were exchanged. The company has a market cap of $1.10 billion, a PE ratio of 88.52 and a beta of 0.66. Diplomat Pharmacy, Inc. has a 12 month low of $12.25 and a 12 month high of $34.80. The stock has a 50 day moving average price of $15.43 and a 200-day moving average price of $15.74.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, August 7th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 7.97%. The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.14 billion. During the same period in the previous year, the firm earned $0.23 earnings per share. Diplomat Pharmacy’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, analysts predict that Diplomat Pharmacy, Inc. will post $0.75 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/13/diplomat-pharmacy-inc-nysedplo-stake-lowered-by-geode-capital-management-llc.html.

A number of equities analysts have recently issued reports on DPLO shares. Mizuho upped their price target on Diplomat Pharmacy from $17.00 to $19.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 16th. TheStreet raised shares of Diplomat Pharmacy from a “d+” rating to a “c-” rating in a report on Thursday. BidaskClub lowered shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Zacks Investment Research raised shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Leerink Swann reissued a “market perform” rating and set a $18.00 price objective (up from $16.00) on shares of Diplomat Pharmacy in a report on Wednesday, May 17th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company’s stock. Diplomat Pharmacy presently has an average rating of “Hold” and a consensus price target of $17.89.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy, Inc. (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.